Item 8.01 Other Events.

On January 21, 2022, the board of directors of AIkido Pharma Inc., a Delaware corporation (the "Company"), authorized a share repurchase program (the "Share Repurchase Program"), pursuant to which the Company may, from time to time, purchase shares of its outstanding stock for an aggregate purchase price not to exceed $3 million dollars. Share repurchases may be executed in open market transactions pursuant to a plan which will be adopted in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934 (the "Exchange Act") and in accordance with Rule 10b-18 of the Exchange Act. The authorization for the Share Repurchase Program may be terminated by the Company in its discretion at any time.

A copy of the press release is attached as Exhibit 99.1 to this report.




Item 9.01.  Financial Statements and Exhibits




d)      Exhibits.



Exhibit No. Description

99.1          Press Release, dated January 24, 2022






                                       1

© Edgar Online, source Glimpses